France's Advicenne H1 net income turns positive as revenue rises 

By Reuters News


Overview

  • France pharmaceutical firm's H1 net income turned positive, reversing prior yr loss

  • Revenue from ordinary activities grew 13% yr/yr, driven by Sibnayal and Likozam sales

  • Company withdrew U.S. marketing application for ADV7103, citing need for additional CMC work


Outlook

  • Advicenne expects continued strong sales growth in Europe and the Middle East in H2 2026

  • Company anticipates a significant reduction in operating expenses in H2 2026

  • Advicenne sees conclusion of safeguard observation period in November 2026 as a key milestone


Result Drivers

  • FRANCE SALES GROWTH - Co said accelerating volume growth for Sibnayal and Likozam in France, following pricing agreements, drove product sales

  • ROYALTY INCREASE - Co said royalties from Sibnayal distributors in Europe and Middle East rose 45%, contributing to revenue growth

  • NON-RECURRING ITEMS - Operating income benefited from reversal of provision and compensation for Likozam early access rebates after pricing agreements


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Net Income

EUR 4.6 mln

H1 Current Operating Income

EUR 5.4 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Advicenne SA is €4.00, about 478.9% above its September 16 closing price of €0.69


Reuters Recommended Reads

  • Sept 17 - Healthcare firm Ramsay Generale de Sante sees 2027 revenue rising by up to 3%

  • Sept 17 - Exosens lifts full-year forecasts again on speedy capacity ramp-up

  • Sept 14 - Contineum, J&J's depression drug fails to meet mid-stage trial goal


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.